RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function

Cell Death and Disease

Volumn 8, Issue 2, 2017, Pages

  Hänggi, Kay ^a   Vasilikos, Lazaros ^a   Valls, Aida Freire ^b   Yerbes, Rosario ^b   Knop, Janin ^a   Spilgies, Lisanne M ^a   Rieck, Kristy ^a   Misra, Tvisha ^a   Bertin, John ^a   Gough, Peter J ^c   Schmidt, Thomas ^b   De Almodòvar, Carmen Ruiz ^b   Wong, W Wei Lynn ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN KINASE 1; RECEPTOR INTERACTING PROTEIN KINASE 3; UNCLASSIFIED DRUG; VASCULOTROPIN; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK1 PROTEIN, MOUSE; RIPK3 PROTEIN, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRAVASATION; HUMAN; HUMAN CELL; METASTASIS; MOUSE; MOUSE MODEL; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR MICROENVIRONMENT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; APOPTOSIS; BONE MARROW; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL DEATH; CELL LINE; EXPERIMENTAL MELANOMA; INFLAMMATION; METABOLISM; NECROSIS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; BONE MARROW; CAPILLARY PERMEABILITY; CELL DEATH; CELL LINE; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NECROSIS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85011579270     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2017.20     Document Type: Article

References (46)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M , et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112-1123.
3. Zhang D-W, Shao J, Lin J, Zhang N, Lu B-J, Lin S-C , et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
4. Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ , et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 2013; 288: 31268-31279.
5. He S, Wang L, Miao L, Wang T, Du F, Zhao L , et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100-1111.
6. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S , et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-495.
7. Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol 2013; 14: 727-736.
8. Sun L, Wang H, Wang Z, He S, Chen S, Liao D , et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
9. Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D , et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014; 343: 1357-1360.
10. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang J-G, Alvarez-Diaz S , et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39: 443-453.
11. Hildebrand JM, Tanzer MC, Lucet IS, Young SN, Spall SK, Sharma P , et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad Sci USA 2014; 111: 15072-15077.
12. Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I , et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 2014; 7: 1-11.
13. Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C , et al. RIPK1 and NF-Bsignaling in dying cells determines cross-priming of CD8+ T cells. Science 2015; 350: 328-334.
14. Koo G-B, Morgan MJ, Lee D-G, KimW-J, Yoon J-H, Koo JS , et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res 2015; 25: 707-725.
15. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A , et al. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 2009; 3: 425-438.
16. Geserick P, Wang J, Schilling R, Horn S, Harris PA, Bertin J , et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis 2015; 6: e1884-12.
17. Vucur M, Reisinger F, Gautheron J, Janssen J, Roderburg C, Cardenas DV , et al. RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8-and JNK-dependent compensatory cell proliferation. Cell Rep 2013; 4: 776-790.
18. Höckendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S , et al. RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell 2016; 30: 75-91.
19. Schmidt SV, Seibert S, Walch-Rückheim B, Vicinus B, Kamionka E-M, Pahne-Zeppenfeld J , et al. RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1 Release, and Efficient Paracrine Dendritic Cell Activation. Oncotarget 2015; 6: 8635-8647.
20. Bozec D, Iuga AC, Roda G, Dahan S, Yeretssian G. Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis. Oncotarget 2016; 7: 46384-46400.
21. Liu X, Zhou M, Mei L, Ruan J, Hu Q, Peng J , et al. Key roles of necroptotic factors in promoting tumor growth. Oncotarget 2016; 7: 22219-22233.
22. Seifert L, Werba G, Tiwari S, Ly NNG, Alothman S, Alqunaibit D , et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 2016; 532: 1-17.
23. Moriwaki K, Balaji S, Mcquade T, Malhotra N, Kang J, Chan FK-M. The necroptosis adaptor RIPK3 promotes injury-induced cytokine expression and tissue repair. Immunity 2014; 41: 567-578.
24. Wong WW-L, Vince JE, Lalaoui N, Lawlor KE, Chau D, Bankovacki A , et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1-and RIPK3-dependent manner. Blood 2014; 123: 2562-2572.
25. Strilic B, Yang L, Albarrán-Juárez J, Wachsmuth L, Han K, Müller UC , et al. Tumour-cellinduced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature 2016; 536: 215-218.
26. Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H , et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell 2014; 56: 481-495.
27. Graslkraupp B, Ruttkaynedecky B, Koudelka H, Bukowska K, Bursch W, Schultehermann R. In-situ detection of fragmented DNA (Tunel assay) fails to discriminate among apoptosis, necrosis, and autolytic cell-death-a cautionary note. Hepatology 1995; 21: 1465-1468.
28. Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR , et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-225.
29. Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A , et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 2012; 22: 91-105.
30. Garciá-Román J, Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett 2013; 335: 259-269.
31. Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F , et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98: 147-157.
32. Murakami M, Nguyen LT, Zhuang ZW, Zhang ZW, Moodie KL, Carmeliet P , et al. The FGF system has a key role in regulating vascular integrity. J Clin Invest 2008; 118: 3355-3366.
33. Li X, Padhan N, Sjöström EO, Roche FP, Testini C, Honkura N , et al. VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nat Commun 2016; 7: 11017.
34. McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 2005; 280: 20995-21003.
35. Luedde M, Lutz M, Carter N, Sosna J, Jacoby C, Vucur M , et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res 2014; 103: 206-216.
36. Pierdomenico M, Negroni A, Stronati L, Vitali R, Prete E, Bertin J , et al. Necroptosis is active in children with inflammatory bowel disease and contributes to heighten intestinal inflammation. Am J Gastroenterol 2013; 109: 279-287.
37. Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T , et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 2014; 157: 1175-1188.
38. Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P , et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 2014; 157: 1189-1202.
39. Kaiser WJ, Daley-Bauer LP, Thapa RJ, Mandal P, Berger SB, Huang C , et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc Natl Acad Sci USA 2014; 111: 7753-7758.
40. Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M , et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol 2014; 192: 5476-5480.
41. Shutinoski B, Alturki NA, Rijal D, Bertin J, Gough PJ, Schlossmacher MG , et al. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo. Cell Death Differ 2016; 23: 1-10.
42. Newton K, Dugger DL, Maltzman A, Greve JM, Hedehus M, Martin-McNulty B , et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ 2016; 23: 1-12.
43. Sun Z, Li X, Massena S, Kutschera S, Padhan N, Gualandi L , et al. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J Exp Med 2012; 209: 1363-1377.
44. Cursi S, Rufini A, Stagni V, Condò I, Matafora V, Bachi A , et al. Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J 2006; 25: 1895-1905.
45. Godwin A, Sharma A, Yang W-L, Wang Z, Nicastro J, Coppa GF , et al. Receptor-interacting protein kinase 3 deficiency delays cutaneous wound healing. PLoS ONE 2015; 10: e0140514.
46. Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol 2004; 24: 1464-1469.